Efgartigimod
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 443 publications
Chronic Inflammatory Demyelinating Polyneuropathy: Update on Diagnosis and Treatment.
Journal: Journal of clinical neuromuscular disease
Published: September 02, 2026
Fatal Myocarditis Relapse in a Patient with Myasthenia Gravis Treated with Efgartigimod Alfa: A Case Report.
Journal: Journal of clinical neuromuscular disease
Published: September 02, 2026
Neonatal Fc receptor (FcRn) inhibition and the implications for inflammatory bowel disease and co-existing immune-mediated diseases.
Journal: Expert review of gastroenterology & hepatology
Published: August 15, 2026
New horizons for autoimmune hyperthyroidism with FcRn blockers.
Journal: Current opinion in endocrinology, diabetes, and obesity
Published: August 06, 2026
Prospective study of efgartigimod in severe myasthenia gravis exacerbations requiring ventilatory or enteral support.
Journal: Journal of neuromuscular diseases
Published: August 04, 2026
Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP.
Journal: Platelets
Published: July 28, 2026
Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.
Journal: Current medical research and opinion
Published: July 24, 2026
Perioperative Use of Efgartigimod Alfa, a Neonatal Fc Receptor Antagonist, to Reduce Antiphospholipid Antibody Titers and Thrombotic Risk in a Kidney Transplant Recipient.
Journal: Kidney medicine
Published: July 19, 2026
Interstitial lung disease and primary Sjögren's syndrome combined with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder: a case report
Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Published: June 29, 2026
Inebilizumab (Uplizna) for myasthenia gravis.
Journal: The Medical letter on drugs and therapeutics
Published: June 25, 2026
Functional Profiling of Acetylcholine Receptor Antibodies Informs Therapeutic Outcome of FcRn Inhibitor Therapy in Myasthenia Gravis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: June 17, 2026
Efgartigimod as rescue therapy in refractory anti-GABAB receptor encephalitis: a case report.
Journal: Journal of neurology
Published: June 11, 2026
Last Updated: 09/26/2026